Roche, Mylan announce agreement on biosimilar to Herceptin

Roche, its subsidiary Genentech and Mylan today announced an agreement settling the legal battle between the groups for biosimilar to Roche-Genentech’s Herceptin, co-developed by Mylan and India-based Biocon. As part of the agreement, Mylan will obtain a global commercialization license for MYL-1401O or trastuzumab, with the sole exception of Japan, Brazil and Mexico. For its part, Mylan will drop two patent infringement lawsuits against Genentech. Mylan is already commercializing the biosimilar in some emerging markets and is waiting for the FDA approval to launch it in the US. Herceptin is the top blockbuster for the Basel-based group, generating sales for $6.7bn. (Source: Endpoints)